105 related articles for article (PubMed ID: 31262909)
1.
Czumaj A; Zabielska J; Pakiet A; Mika A; Rostkowska O; Makarewicz W; Kobiela J; Sledzinski T; Stelmanska E
Anticancer Res; 2019 Jul; 39(7):3815-3822. PubMed ID: 31262909
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
[TBL] [Abstract][Full Text] [Related]
3. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
4. Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer Cells (PANC-1).
Sokolowska E; Presler M; Goyke E; Milczarek R; Swierczynski J; Sledzinski T
Anticancer Res; 2017 Nov; 37(11):6321-6327. PubMed ID: 29061815
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
Cioccoloni G; Aquino A; Notarnicola M; Caruso MG; Bonmassar E; Zonfrillo M; Caporali S; Faraoni I; Villivà C; Fuggetta MP; Franzese O
J Chemother; 2020 Feb; 32(1):30-40. PubMed ID: 31775585
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal.
Chuang HY; Chang YF; Hwang JJ
Biomed Pharmacother; 2011 Jul; 65(4):286-92. PubMed ID: 21723078
[TBL] [Abstract][Full Text] [Related]
8. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.
Agostini M; Almeida LY; Bastos DC; Ortega RM; Moreira FS; Seguin F; Zecchin KG; Raposo HF; Oliveira HC; Amoêdo ND; Salo T; Coletta RD; Graner E
Mol Cancer Ther; 2014 Mar; 13(3):585-95. PubMed ID: 24362464
[TBL] [Abstract][Full Text] [Related]
9. FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth.
Wei W; Qin B; Wen W; Zhang B; Luo H; Wang Y; Xu H; Xie X; Liu S; Jiang X; Wang M; Tang Q; Zhang J; Yang R; Fan Z; Lyu H; Lin J; Li K; Lee MH
Signal Transduct Target Ther; 2023 May; 8(1):187. PubMed ID: 37202390
[TBL] [Abstract][Full Text] [Related]
10. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
11. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration.
Zaytseva YY; Harris JW; Mitov MI; Kim JT; Butterfield DA; Lee EY; Weiss HL; Gao T; Evers BM
Oncotarget; 2015 Aug; 6(22):18891-904. PubMed ID: 25970773
[TBL] [Abstract][Full Text] [Related]
13. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
Chang L; Wu P; Senthilkumar R; Tian X; Liu H; Shen X; Tao Z; Huang P
J Cancer Res Clin Oncol; 2016 Jan; 142(1):59-72. PubMed ID: 26109148
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation.
Zhang C; Zhang Y; Dong Y; Zi R; Wang Y; Chen Y; Liu C; Wang J; Wang X; Li J; Liang H; Ou J
Cell Death Discov; 2024 Jan; 10(1):41. PubMed ID: 38263401
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2012 Nov; 1820(11):1764-73. PubMed ID: 22877747
[TBL] [Abstract][Full Text] [Related]
18. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
Ohol YM; Wang Z; Kemble G; Duke G
PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
[TBL] [Abstract][Full Text] [Related]
19. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
[TBL] [Abstract][Full Text] [Related]
20. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
